Immune Cells Infiltration Assay

The Immune Cell Infiltration Assay evaluates the effectiveness of immunotherapeutic drugs by assessing
the ability of immune cells to infiltrate three-dimensional tissues (e.g. cancer tissues) and trigger tumor apoptosis. This assay is especially valuable for testing novel immunotherapeutic strategies, offering critical insights into the tumor-immune interplay that distinguishes “hot” tumors—characterized by robust immune cell presence—from “cold” tumors with minimal infiltration.

Purpose of the Test

By integrating advanced 3D tumor models with diverse immune cell populations in circulation within the immune-on-chip platform, this assay quantitatively measures both the extent of immune cell infiltration into the tumor and their capacity to induce tumor cell apoptosis. The dynamic fluidic environment provides a unique and highly predictive evaluation of immunotherapeutic efficacy in a fully humanized immune-tumor model.

Aligned with the guidelines of regulatory agencies such as the FDA and EMA, this assay plays a pivotal role in the preclinical assessment of immunotherapies. It ensures that critical data on tumor immunogenicity and immune cell-mediated cytotoxicity are rigorously collected, supporting the safety and efficacy profiles required for successful clinical development.

The MIVO® Advantage: A Superior Predictive Model

Incorporating dynamic fluid flow, this immune on chip based assay has the unicity to simulate physiological immune cell trafficking and tumor penetration. Therefore,
it offers significant advantages over both traditional and simplistic static assays and expensive animal models by promoting uniform immune cell distribution and improving drug delivery parameters.(ref immuno)

Our Unique Value Proposition

Dynamic Fluidic System for Physiological Relevance: The incorporation of dynamic fluid flow simulates immune cells circulation (e.g. T cells, NK, PBMC), promoting enhanced immune cell migration and uniform tumor infiltration, thereby providing a realistic in vitro representation of in vivo conditions.

Versatile Immune Cell Integration: Supporting a wide range of immune cell types, the assay is ideally suited for testing various immunotherapeutic agents and strategies aimed at augmenting immune-mediated tumor cell apoptosis.

Quantitative Apoptotic Readout: Robust, quantitative metrics of tumor apoptosis induced by infiltrating immune cells enable the optimization of immunotherapy regimens and provide critical insights into the effectiveness of novel treatments.